Total votes: 6

Viralytics is listed on the Australia Securities Exchange (VLA) and is quoted on the OTC market.(VRACY)

Some Financial details:

Cash on hand on 30 September 2011 was $4.0 million.

Additional funds of approximately $700k are expected to be received in November 2011 from a Research and Development tax refund due from the Australian Taxation Office. 

Viralytics is focused on its virotherapy treatment for a range of cancers, including melanoma, breast and prostate. Viralytics has acquired, by license, an anti-cancer virotherapy technology using coxsackievirus and echovirus. As of June 30, 2009, the Company has three clinical trials of CAVATAK underway at three Australian hospitals. Cavatak is the trade name of Coxsackievirus A21 (CVA21). Subsequent to June 30, 2009, the Company announced four new hospital sites joining these trials. Its product portfolio includes Echovirus-1 and CVA21 DAF. 

In January 2010 the company announced that the the Pahse I CAVATAK trial was successful with all patients tolerating the treatment and none of them exhibiting any product related serious adverse events. The Secondary objective of the trial also monitored the injected tumour and other distant tumours for signs of CAVATAK™ activity against actively progressing metastatic melanoma. Injected tumours of one third of patients reduced in size, while the injected tumours of a further 22% of patients remained stable. Measurement of other distant tumours in the patients showed that the overall disease was stabilized in two of the patients. It should be noted that as this trial was a safety trial the Company was only allowed to inject a single tumour. This restriction will not apply in Phase II trials. All patients in the trial had late stage disease and had previously failed or rejected standard
therapies.

Possible Upcoming Events:
The Company has chosen to conduct its planned Phase II melanoma trial under a USA Investigational New Drug (IND) application to begin Q4 2011 or Q1 2012.

Phase I trial results for breast cancer, head & neck cancer and prostate cancer are also expected 2011-12.

Competition:

 - Biovex (acquired by Amgen in 2010 for a possisble $1 billion transaction)
 - Oncolytic Biotech (market cap above $400M in Jan. 2011)